Price movement over the last 24 hours
Agilent Technologies Inc vs Bank of New York Mellon Corp — how do they compare? Agilent Technologies Inc trades at $128.79 (market cap $37.04B), while Bank of New York Mellon Corp trades at $149.66 (market cap $104.95B). The key difference: Bank of New York Mellon Corp is far larger — about 2.8× Agilent Technologies Inc's market cap, and Bank of New York Mellon Corp pays the higher dividend (1.39%). Which is the better fit depends on your goals.
| A | BNY | |
|---|---|---|
Market Cap | $37.04B | $104.95B |
Sector | Health | Financials |
52-Week High | $157.20 | $152.91 |
52-Week Low | $110.24 | $92.69 |
Enterprise Value | $38.59B | — |
Dividend Yield | 0.78% | 1.39% |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
BNY Mellon stock trades at $152.91, up 4.29% on the day, near its consensus price target of $156. The stock shows strong momentum with three consecutive quarterly earnings beats and a bullish technical trend. Recent news highlights a planned 19% dividend increase to $0.63 per share and expansion into digital asset services, reflecting strategic growth initiatives. Revenue has grown steadily from $16.0B in 2022 to $19.8B in 2025, with net income margin improving to 29.21%.
The outlook remains positive with analyst consensus leaning toward 'Hold' but no 'Sell' ratings. Key opportunities include dividend growth and digital finance expansion, while risks involve high investing cash outflows and interest expense pressures. The stock's valuation at a P/E of 18.61 appears reasonable given profitability trends, but investors should monitor execution on capital investments.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.
Read more on BNY →